[go: up one dir, main page]

AT516600A5 - Herstellung von faktor h (fh) und fh-derivaten aus plasma - Google Patents

Herstellung von faktor h (fh) und fh-derivaten aus plasma

Info

Publication number
AT516600A5
AT516600A5 ATA9249/2010A AT92492010A AT516600A5 AT 516600 A5 AT516600 A5 AT 516600A5 AT 92492010 A AT92492010 A AT 92492010A AT 516600 A5 AT516600 A5 AT 516600A5
Authority
AT
Austria
Prior art keywords
plasma
factor
derivatives
preparation
relates
Prior art date
Application number
ATA9249/2010A
Other languages
English (en)
Other versions
AT516600B1 (de
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of AT516600B1 publication Critical patent/AT516600B1/de
Publication of AT516600A5 publication Critical patent/AT516600A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft ein Verfahren zum Herstellen einer angereicherten Faktor H Zusammensetzung aus Plasma. Weiters betrifft die Erfindung pharmazeutische Zusammensetzungen, die den angereicherte Faktor H enthalten.
ATA9249/2010A 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma AT516600B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22796809P 2009-07-23 2009-07-23
PCT/US2010/043151 WO2011011753A1 (en) 2009-07-23 2010-07-23 Manufacture of factor h (fh) and fh-derivatives from plasma

Publications (2)

Publication Number Publication Date
AT516600B1 AT516600B1 (de) 2016-07-15
AT516600A5 true AT516600A5 (de) 2016-07-15

Family

ID=42827367

Family Applications (2)

Application Number Title Priority Date Filing Date
ATA50852/2014A AT514675B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma
ATA9249/2010A AT516600B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ATA50852/2014A AT514675B1 (de) 2009-07-23 2010-07-23 Herstellung von faktor h (fh) und fh-derivaten aus plasma

Country Status (3)

Country Link
US (3) US8304524B2 (de)
AT (2) AT514675B1 (de)
WO (1) WO2011011753A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5577354B2 (ja) 2009-01-29 2014-08-20 フォーサイト・ビジョン フォー・インコーポレーテッド 治療装置
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) * 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
EA201390156A1 (ru) 2010-07-23 2014-01-30 Бакстер Интернэшнл Инк. ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
HRP20211909T1 (hr) * 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CA2882317C (en) * 2012-09-26 2021-04-06 Bone Therapeutics S.A. Formulations comprising solvent/detergent-treated plasma and hyaluronic acid for treating musculoskeletal diseases
EP2968444A1 (de) 2013-03-14 2016-01-20 Baxalta Incorporated Faktor h zur behandlung von rheumatoider arthritis
SI2968457T1 (sl) 2013-03-14 2018-11-30 Baxalta Incorporated Faktor H za transplantacijo
AU2013203048A1 (en) * 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) * 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US20170233458A1 (en) * 2015-09-29 2017-08-17 Kieu Hoang Method of manufacturing intravenous immunoglobulin from fraction iii
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
EP3377009B1 (de) 2015-11-20 2020-10-28 ForSight Vision4, Inc. Poröse strukturen für arzneimittelabgabevorrichtungen mit verlängerter freisetzung
US10525107B2 (en) * 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN119345230A (zh) 2018-10-26 2025-01-24 万能溶剂有限公司 血浆和血浆组分用于改善疼痛的用途
ES2974790T3 (es) * 2018-11-27 2024-07-01 Gambro Lundia Ab Preparación de un aparato de tratamiento sanguíneo extracorpóreo
CN113045634B (zh) * 2019-12-28 2023-04-28 四川远大蜀阳药业有限责任公司 一种补体h因子制备方法
US20240024416A1 (en) * 2020-10-30 2024-01-25 Gemini Therapeutics Sub, Inc. Methods for treating inflammatory ocular diseases with complement factor h
WO2023170553A1 (en) 2022-03-07 2023-09-14 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
TW202400621A (zh) * 2022-05-02 2024-01-01 日商武田藥品工業股份有限公司 經由超濾自血漿製備科恩池濃縮物之方法
WO2025068923A2 (en) 2023-09-26 2025-04-03 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA
WO2025253181A1 (en) 2024-06-07 2025-12-11 Takeda Pharmaceutical Company Limited Apparatus and methods for monitoring a polypeptide type concentration in a multi-step biologic production process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma
US20080318841A1 (en) * 2005-12-07 2008-12-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies S.A. Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP1221918B1 (de) 1999-10-21 2005-03-16 Alcon Inc. Medikamentenversorgung der sub-tenon
NZ608860A (en) * 2005-02-14 2014-10-31 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
CA2627264A1 (en) * 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080318841A1 (en) * 2005-12-07 2008-12-25 Laboratoire Francais Du Fractionnement Et Des Biotechnologies S.A. Method For Preparing a Factor H Concentrate and the Use Thereof in the Form of a Drug
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Also Published As

Publication number Publication date
US8304524B2 (en) 2012-11-06
US20130102537A1 (en) 2013-04-25
AT514675A3 (de) 2018-05-15
US20110021432A1 (en) 2011-01-27
AT514675B1 (de) 2019-05-15
US20130303731A1 (en) 2013-11-14
US9109044B2 (en) 2015-08-18
AT516600B1 (de) 2016-07-15
US8822656B2 (en) 2014-09-02
AT514675A2 (de) 2015-02-15
WO2011011753A1 (en) 2011-01-27

Similar Documents

Publication Publication Date Title
AT516600A5 (de) Herstellung von faktor h (fh) und fh-derivaten aus plasma
EP3964516A4 (de) Oxaazachuinazolin-7( 8h)-ketonverbindung, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MY142029A (en) Phenoxyacetic acid derivatives
GEP20125643B (en) Aurora kinase modulators and method of using same
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
EA201200794A1 (ru) Триазолопиридины
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
MX2007013084A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion.
SG10201805198TA (en) 18f - fluciclovine compositions in citrate buffers
ATE528305T1 (de) Verfahren zur herstellung oder reinigung von olmesartan-medoxomil oder von olmesartan- medoxomil-hydrohalid-salz
UA99447C2 (ru) Способ получения силденафила
ATE524469T1 (de) Alkinylarylverbindungen und salze davon, diese enthaltende pharmazeutische zusammensetzungen, verfahren zu deren herstellung und deren verwendungen
EP2698142A3 (de) Zahnfüllungsmaterialien und Zahnlacke zur Hemmung der Biofilmbildung von Streptococcus mutans und deren Herstellung
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
ATE444950T1 (de) Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid
ATE536864T1 (de) Metoprololsuccinat tabletten mit verlängerter freisetzung und verfahren für deren herstellung
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
GEP20135733B (en) Novel diazeniumdiolate derivatives, their preparation method and pharmaceutical compositions containing them
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
MY150497A (en) New camptothecin analogue compounds, a process for their preparation and pharmaceutical compositions containing them
ATE528295T1 (de) Trisubstituierte 3,4-dihydro-1h-isochinolin- verbindung, verfahren zu ihrer herstellung und ihre anwendung
EP2415762A3 (de) Verfahren zur Herstellung von Aminoarylalkylverbindungen
TW200613315A (en) Estradiol prodrugs

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: BAXALTA GMBH, CH

Effective date: 20160830

Owner name: BAXALTA INCORPORATED, US

Effective date: 20160830

PC Change of the owner

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP

Effective date: 20210719